^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
Published date:
12/06/2019
Excerpt:
...Patients with HER2 3+ overexpression…at baseline demonstrated significantly better survival (P = .007) or treatment response (P = .016), respectively….HER2 3+ overexpression...are potentially predictive for survival and treatment response, respectively.
DOI:
10.1200/JCO.19.01814
Trial ID:
